IMVT
Immunovant Inc
34.00$
-1.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +143.6% | -6.3% | -11.6% | -12.5% | -18.4% | +84.4% | -14.8% | -11.9% | +80.5% | -9.1% | -10.9% | |
| – | +144.1% | -6.3% | -11.5% | -13.9% | -18.7% | +86.1% | -15.1% | -12.0% | +81.8% | -9.0% | -10.3% | |
| – | +156.0% | -8.0% | -11.9% | -15.5% | -20.8% | +90.6% | -16.1% | -12.9% | +90.6% | -9.3% | -11.6% | |
| – | +156.0% | -8.0% | -11.9% | -15.5% | -20.8% | +90.6% | -16.1% | -12.9% | +90.6% | -9.3% | -11.6% | |
| – | -27.6% | +434.8% | -56.1% | -22.4% | +18.6% | +12.9% | -22.9% | +1.8% | -16.6% | +140.2% | -82.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -20.3% | +52.5% | -8.0% | +48.1% | +2.5% | +0.7% | -23.1% | +19.6% | +4.7% | +57.6% | +12.1% | |
| – | -20.3% | +51.4% | -7.4% | +48.1% | +2.5% | +0.7% | -23.1% | +19.6% | +4.7% | +57.6% | +12.1% | |
| – | -50.2% | -54.9% | -50.0% | -31.9% | -51.1% | +326.1% | – | – | – | – | – | |
| – | -47.9% | +83.0% | +54.2% | +87.8% | -4.4% | -10.9% | -55.6% | -11.8% | +24.6% | -12.5% | +34.4% | |
| – | +169.8% | -9.1% | -11.8% | -17.6% | -21.5% | +100.6% | -14.0% | -14.6% | +89.7% | -13.5% | -13.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.2% | +0.6% | +0.5% | +0.3% | +0.3% | +3.2% | +12.7% | +1.6% | +4.5% | +12.2% | +0.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.